These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28540167)

  • 41. [Association of baseline alanine aminotransferase levels with therapeutic effects of entecavir and interferon-
    Xiao Z; Zhou F; Zhou B; Yang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Feb; 39(2):150-155. PubMed ID: 30890501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of IFN-γ and IL-12 expressions on intrauterine transmission in HBsAg-positive parturientsin late pregnancy].
    Zhang L; Wang HR; Shao YZ; Yan M; Fu T; Hu N; Gao J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Sep; 40(9):1077-1083. PubMed ID: 31594149
    [No Abstract]   [Full Text] [Related]  

  • 45. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
    Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
    Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
    BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Study on the differences of two mouse models of hepatitis B virus infection by transduction with rAAV8-1. 3HBV].
    Wang G; Dong XY; Tian WH; Yu CJ; Zheng G; Gao J; Wang GJ; Wei GC; Zhou YS; Wu XB
    Bing Du Xue Bao; 2012 Sep; 28(5):541-7. PubMed ID: 23233931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Curative effect of Yidu Recipe in treating chronic hepatitis B patients of gan-shen yin-deficiency and damp-heat syndrome type and its influence of T-cell subsets].
    Tang BZ; Li M; Gao YQ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Aug; 30(8):823-7. PubMed ID: 21038650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
    J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.
    Schlaak JF; Tully G; Löhr HF; Gerken G; Meyer zum Büschenfelde KH
    Clin Exp Immunol; 1999 Mar; 115(3):508-14. PubMed ID: 10193426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
    Martin P; Dubois C; Jacquier E; Dion S; Mancini-Bourgine M; Godon O; Kratzer R; Lelu-Santolaria K; Evlachev A; Meritet JF; Schlesinger Y; Villeval D; Strub JM; Van Dorsselaer A; Marchand JB; Geist M; Brandely R; Findeli A; Boukhebza H; Menguy T; Silvestre N; Michel ML; Inchauspé G
    Gut; 2015 Dec; 64(12):1961-71. PubMed ID: 25429051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.
    Zhang L; Wang Q; Zhao P; Hu X; Jiang Y
    Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):514-23. PubMed ID: 24773272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
    Arends P; Rijckborst V; Zondervan PE; Buster E; Cakaloglu Y; Ferenci P; Tabak F; Akarca US; Simon K; Sonneveld MJ; Hansen BE; Janssen HL
    J Viral Hepat; 2014 Dec; 21(12):897-904. PubMed ID: 24444353
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV)
    Ge FL; Si LL; Yang Y; Li YH; Lv ZL; Liu WH; Liao H; Wang J; Zou J; Li L; Li H; Zhang ZL; Wang JB; Lu XC; Xu DP; Bai ZF; Liu Y; Xiao XH
    Front Pharmacol; 2021; 12():756975. PubMed ID: 34776974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Establishment of an HBV chronic hepatitis B infection mouse model by vivo transduction of HBV cccDNA].
    Zhao T; Li X; Yin W; Cai X; Zhang W; Chen F; Lai G; Huang A
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):260-5. PubMed ID: 25173223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.